Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: BI 443651
Drug: Placebo

First Posted Date: 2016-11-29

Last Posted Date: 2019-11-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02976519

Locations: 🇬🇧
The Medicines Evaluation Unit, Manchester, United Kingdom
🇩🇪
Lungenärztliche Praxis, München-Pasing, Germany
🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany

and more 2 locations

Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Olodaterol

First Posted Date: 2016-11-21

Last Posted Date: 2019-03-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02969317

Locations: 🇨🇳
West China Hospital, Chengdu, China

Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ibuprofen
Drug: Pseudoephedrine-HCl

First Posted Date: 2016-11-15

Last Posted Date: 2018-09-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02963701

Locations: 🇿🇦
Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, South Africa

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 754091

First Posted Date: 2016-11-02

Last Posted Date: 2024-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 112

Registration Number: NCT02952248

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada

and more 10 locations

All-Case Surveillance of Prizbind®

Completed

Conditions: Hemorrhage

Interventions: Drug: Prizbind®

First Posted Date: 2016-10-27

Last Posted Date: 2022-09-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1402

Registration Number: NCT02946931

Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset

Phase 3

Completed

Conditions: Stroke

Interventions: Drug: alteplase

First Posted Date: 2016-10-12

Last Posted Date: 2019-08-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 120

Registration Number: NCT02930837

Locations: 🇨🇳
Dongguan People's Hospital, Dongguan, China
🇨🇳
Renmin Hospital of Wuhan University, Wuhan, China
🇨🇳
Yanbian University Hospital, Yanji, China

and more 8 locations

OTIVACTO Spain Non Interventional Study

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2016-10-07

Last Posted Date: 2019-09-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 257

Registration Number: NCT02927795

Locations: 🇪🇸
Centre d'Atenció Primària Calella, Calella (Barcelona), Spain
🇪🇸
Centro de Salud del Barrio de Peral, Cartagena (Murcia), Spain
🇪🇸
Centro de Salud de Torrekua, Eibar (Guipúzcoa), Spain

and more 75 locations

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Phase 3

Completed

Conditions: Thromboembolism

Interventions: Drug: Dabigatran etexilate
Drug: Warfarin

First Posted Date: 2016-09-23

Last Posted Date: 2019-08-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 120

Registration Number: NCT02913326

Locations: 🇮🇳
Caritas Hospital, Kottayam, India
🇮🇳
Mazumdar Shaw Medical centre, Bangalore, India
🇮🇳
Nizam's Institute of Medical Sciences, Hyderabad, India

and more 33 locations

Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima

Completed

Conditions: Acute Pain
Dysmenorrhea

Interventions: Drug: Hyoscine n-butylbromide
Drug: Paracetamol

First Posted Date: 2016-09-21

Last Posted Date: 2019-03-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 360

Registration Number: NCT02910167

Pharmacokinetics and Safety of BI 695501

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI695501Autoinjector
Drug: BI695501 Prefilled syringe

First Posted Date: 2016-09-14

Last Posted Date: 2018-10-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 162

Registration Number: NCT02899338

Locations: 🇧🇪
SGS Life Sciences Services, Antwerpen, Belgium
🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy